Acute promyelocytic leukemia (APL) is a malignant and fatal disease. The authors report here for the first time in the world that a chemically synthesized diarsenic trisulfide (DATS, As 2S 3) used alone by mouth can h...Acute promyelocytic leukemia (APL) is a malignant and fatal disease. The authors report here for the first time in the world that a chemically synthesized diarsenic trisulfide (DATS, As 2S 3) used alone by mouth can have a remarkable effect in the treatment. The patient is reported to have attained not only hematological/clinical complete remission, but also cytogenetic and molecular biological remission after treatment. A male 47 year old patient with APL which was not treated before was given DATS by mouth from Nov.18, 1998. The dosage was 0.5 g tid. Promyelocytes in his bone marrow were decreased from 90% to normal range. Alongside, there was normalization of blood platelet count and hemoglobin value. He was discharged with hematological remission on Dec.31, 1998, and attained cytogenetic and molecular biological remission in March 1999. The side effect was minimal.展开更多
William Tongamp,et al.研究了在Cu3AsS4-NaHS-NaOH体系中从高碱性硫砷铜矿浸出液中脱砷的可行性和浸出剂的再生性。首先还原硫元素然后将亚砷酸盐（As（Ⅲ））氧化成砷酸盐（As（Ⅴ））以形成沉淀Na3AsS4。首先,在NaHS-NaOH体系中,用...William Tongamp,et al.研究了在Cu3AsS4-NaHS-NaOH体系中从高碱性硫砷铜矿浸出液中脱砷的可行性和浸出剂的再生性。首先还原硫元素然后将亚砷酸盐（As（Ⅲ））氧化成砷酸盐（As（Ⅴ））以形成沉淀Na3AsS4。首先,在NaHS-NaOH体系中,用三硫化二砷（As2S3）或硫砷铜矿（Cu3AsS4）制备砷质量浓度35g／L以上的溶液。展开更多
文摘Acute promyelocytic leukemia (APL) is a malignant and fatal disease. The authors report here for the first time in the world that a chemically synthesized diarsenic trisulfide (DATS, As 2S 3) used alone by mouth can have a remarkable effect in the treatment. The patient is reported to have attained not only hematological/clinical complete remission, but also cytogenetic and molecular biological remission after treatment. A male 47 year old patient with APL which was not treated before was given DATS by mouth from Nov.18, 1998. The dosage was 0.5 g tid. Promyelocytes in his bone marrow were decreased from 90% to normal range. Alongside, there was normalization of blood platelet count and hemoglobin value. He was discharged with hematological remission on Dec.31, 1998, and attained cytogenetic and molecular biological remission in March 1999. The side effect was minimal.
